Reviewer: Nat Pernick, M.D. (see Reviewers page)
Revised: 4 December 2011, last major update November 2011
Copyright: (c) 2002-2011, PathologyOutlines.com, Inc.
● Marker of terminally differentiated smooth muscle cells, first described in 1996 (J Cell Biol 1996;134:401)
● Distinction of cytoplasmic from nuclear staining may be important
Uses by Pathologists
● In urothelial carcinoma, may help distinguish invasion of muscularis propria (positive) from muscularis mucosa (weak/negative, Am J Surg Pathol 2010;34:792, Am J Surg Pathol 2009;33:91), but there may be overlap of staining between the two layers (Virchows Arch 2011;458:665, Am J Surg Pathol 2010;34:418)
● In esophagus, stains weaker in neuromuscularis mucosa, but may need for both layers to be present simultaneously to accurately interpret depth of invasion (Am J Surg Pathol 2011;35:55)
Positive staining - normal
● Differentiated smooth muscle cells
Positive staining - disease
● Cytoplasmic staining: benign smooth muscle tumors, GI leiomyosarcomas (24%, Am J Surg Pathol 2009;33:1795)
● Nuclear staining: GI leiomyosarcomas (41%), GIST (22%)
● Striated muscle, myofibroblasts, myoepithelial cells, pericytes
● Negative cytoplasmic staining in dedifferentiated liposarcoma, desmoid tumor, GIST, inflammatory myofibroblastic tumor, MPNST, schwannoma
End of Stains > Smoothelin
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).